| Similar Articles |
|---|
 |
The Motley Fool
October 31, 2007
Brian Lawler |
Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.   |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
The Motley Fool
February 28, 2008
Brian Lawler |
Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful. |
The Motley Fool
December 13, 2007
Brian Lawler |
Alpharma Gives to Get The generics drugmaker forecasts its 2008 financials, with guidance of expenses up and income down. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
September 12, 2008
Brian Lawler |
King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders. |
The Motley Fool
February 8, 2008
Brian Lawler |
Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
April 16, 2008
Brian Lawler |
Alpharma's Soothing Guidance Alpharma lowers its financial guidance for 2008. Investors, take note. |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
May 28, 2008
Brian Lawler |
King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another. |
The Motley Fool
December 11, 2008
Brian Orelli |
A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone. |
The Motley Fool
September 29, 2006
Brian Lawler |
Alpharma's Painless Results A new addition to an already successful drug promises good results for investors. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
The Motley Fool
May 2, 2007
Brian Lawler |
Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about. |
The Motley Fool
November 5, 2007
Brian Lawler |
King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
The Motley Fool
February 28, 2007
Brian Lawler |
Alpharma's Just All Right Drugmaker Alpharma announces its fourth-quarter financial results and reiterates guidance for 2007. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
April 2, 2007
Brian Lawler |
Pain Therapeutics Pares Shares The small drugmaker announces a share buyback. |
The Motley Fool
July 24, 2007
Brian Lawler |
Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it. |
The Motley Fool
October 6, 2008
Brian Orelli |
Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated. |
The Motley Fool
October 5, 2007
Brian Lawler |
OxyContin in the Crosshairs Again The state of Kentucky sues Purdue Frederick over the monetary burden that abusers of the drug OxyContin place on counties within the state. |
The Motley Fool
January 25, 2008
Brian Orelli |
Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
American Family Physician
September 15, 2000 |
The Nicotine Patch How do I use the patch?... What do I need to tell my doctor before I use the patch?... My skin tingles under the patch. Is that normal?... Can I wear the patch in the shower?... What if the patch falls off?... |
